Theriva Biologics (TOVX) Common Equity (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Common Equity of $15.4 million for Q1 2026, down 0.63% year-over-year from $15.5 million in Q1 2025, and little changed quarter-over-quarter from $15.4 million in Q4 2025.
Theriva Biologics (TOVX) Common Equity (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Common Equity for 17 consecutive years, with $15.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 0.63% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (down 0.63% YoY), while the FY2025 annual figure was $15.4 million, down 19.32% from the prior year.
- Common Equity steadied at $15.4 million in Q1 2026 per TOVX's latest filing, from $15.4 million in the prior quarter.
- Across five years, Common Equity topped out at $68.0 million in Q1 2022 and bottomed at $6.7 million in Q3 2025.
- Historically, Common Equity has averaged $33.8 million across 5 years, with a median of $31.4 million in 2024.
- Annual changes were most pronounced in 2025 — Common Equity plunged 72.65% — and 2026, when it fell 0.63%.
- Theriva Biologics' Common Equity stood at $51.8 million in 2022, then decreased by 28.68% to $37.0 million in 2023, then tumbled by 48.42% to $19.1 million in 2024, then declined by 19.32% to $15.4 million in 2025, then gained by 0.1% to $15.4 million in 2026.
- Business Quant data shows TOVX's Common Equity at $15.4 million in Q1 2026, $15.4 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Theriva Biologics | 10.90 Mn | 10.90 Mn | - | 12.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.19 Mn |
| Mar 31, 2026 | 15.40 Mn |
| Dec 31, 2025 | 15.38 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 10.62 Mn |
| Mar 31, 2025 | 15.50 Mn |
| Dec 31, 2024 | 19.07 Mn |
| Sep 30, 2024 | 24.64 Mn |
| Jun 30, 2024 | 25.90 Mn |
| Mar 31, 2024 | 31.39 Mn |
| Dec 31, 2023 | 36.96 Mn |
| Sep 30, 2023 | 41.15 Mn |
| Jun 30, 2023 | 45.02 Mn |
| Mar 31, 2023 | 47.85 Mn |
| Dec 31, 2022 | 51.83 Mn |
| Sep 30, 2022 | 56.39 Mn |
| Jun 30, 2022 | 62.22 Mn |
| Mar 31, 2022 | 68.03 Mn |
| Dec 31, 2021 | 65.41 Mn |
| Sep 30, 2021 | 70.56 Mn |